NCT05528341View on ClinicalTrials.gov

NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 26, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Relapsed/Refractory Solid Tumors
Interventions
BIOLOGICAL

NKG2D-CAR-NK92 cells

NKG2D-CAR-NK92 cells will be administered intravenously over 1h. The starting dose of NKG2D-CAR-NK92 cells will be 0.5×10\^6-2×10\^6/kg, twice a week. The first evaluation of the efficacy after 3 weeks of treatment.

Trial Locations (1)

453000

RECRUITING

The first Affiliated Hospital of Xinxiang Medical University, Xinxiang

All Listed Sponsors
lead

Xinxiang medical university

OTHER